EZN-2208 (PEG-SN38) Overcomes ABCG2-Mediated Topotecan Resistance in BRCA1-Deficient Mouse Mammary Tumors

• Serge A. L. Zander,

  Affiliation Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

  ⨯
• Wendy Sol,

  Affiliation Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

  ⨯
• Lee Greenberger,

  Current address: Bristol-Myers Squibb, Princeton, New Jersey, United States of America

  Affiliation Department of Pharmacology, Enzon Pharmaceuticals Inc., Piscataway, New Jersey, United States of America

  ⨯
• Yixian Zhang,

  Affiliation Department of Pharmacology, Enzon Pharmaceuticals Inc., Piscataway, New Jersey, United States of America

  ⨯
• Olaf van Tellingen,

  Affiliation Department of Clinical Chemistry, The Netherlands Cancer Institute, Amsterdam, The Netherlands

  ⨯
• Jos Jonkers,

  Affiliation Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

  ⨯
• Piet Borst,

  Affiliation Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

  ⨯
• Sven Rottenberg

  * E-mail: s.rottenberg@nki.nl

  Affiliation Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands

  ⨯